Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor
Open Access
- 1 January 2014
- journal article
- case report
- Published by Springer Science and Business Media LLC in World Journal of Surgical Oncology
- Vol. 12 (1), 220
- https://doi.org/10.1186/1477-7819-12-220
Abstract
Necrolytic migratory erythma (NME) is an obligatory paraneoplastic syndrome. Here we describe a woman admitted to the dermatology ward with NME which was later found to be associated with glucagonoma, a slow-growing, rare pancreatic neuroendocrine tumor. Even more rarely, the tumor was located in the pancreas head, while most of such lesions are located in the distal pancreas. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. After surgical removal of the tumor, the patient’s cutaneous and systemic features resolved. It is therefore imperative that clinicians recognize NME early in order to make an accurate diagnosis and to provide treatment for this rare tumor.Keywords
This publication has 18 references indexed in Scilit:
- Necrolytic Migratory Erythema as the First Manifestation of GlucagonomaCase Reports in Surgery, 2012
- Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumourClinical Endocrinology, 2011
- Pancreatic Neuroendocrine TumorsEndocrine Research, 2011
- Glucagonoma syndrome and necrolytic migratory erythemaInternational Journal of Dermatology, 2010
- Surgical aspects of neuroendocrine tumoursEuropean Journal of Cancer, 2009
- Pancreatic neuroendocrine tumorsCancer, 2009
- Rare endocrine tumours of the GI tractBest Practice & Research Clinical Gastroenterology, 2005
- Necrolytic Migratory Erythema: Case Report and Clinical ReviewJournal of Cutaneous Medicine and Surgery, 2003
- The Glucagonoma Syndrome Clinical and Pathologic Features in 21 PatientsMedicine, 1996
- Gucagonoma syndrome is an underdiagnosed clinical entityThe American Journal of Surgery, 1990